Trust Point Inc. Has $408,000 Stake in Phreesia, Inc. (NYSE:PHR)

Trust Point Inc. increased its stake in shares of Phreesia, Inc. (NYSE:PHR) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 17,887 shares of the company’s stock after purchasing an additional 607 shares during the quarter. Trust Point Inc.’s holdings in Phreesia were worth $408,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PHR. Wesbanco Bank Inc. acquired a new stake in Phreesia during the third quarter valued at $593,000. Essex Investment Management Co. LLC lifted its holdings in shares of Phreesia by 44.7% during the 3rd quarter. Essex Investment Management Co. LLC now owns 117,849 shares of the company’s stock valued at $2,686,000 after buying an additional 36,406 shares during the last quarter. Inspire Investing LLC acquired a new stake in shares of Phreesia during the 3rd quarter valued at about $416,000. Diversified Trust Co grew its stake in shares of Phreesia by 12.9% in the 3rd quarter. Diversified Trust Co now owns 24,356 shares of the company’s stock valued at $555,000 after buying an additional 2,782 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Phreesia in the third quarter worth approximately $954,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 14,110 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.03, for a total value of $367,283.30. Following the completion of the sale, the general counsel now owns 121,003 shares in the company, valued at approximately $3,149,708.09. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Chaim Indig sold 5,295 shares of Phreesia stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $123,108.75. Following the sale, the chief executive officer now directly owns 1,223,736 shares in the company, valued at approximately $28,451,862. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Allison C. Hoffman sold 14,110 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $26.03, for a total transaction of $367,283.30. Following the completion of the transaction, the general counsel now directly owns 121,003 shares of the company’s stock, valued at $3,149,708.09. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,014 shares of company stock worth $1,012,860 over the last three months. Company insiders own 5.80% of the company’s stock.

Analysts Set New Price Targets

PHR has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Royal Bank of Canada reissued a “sector perform” rating and set a $23.00 target price on shares of Phreesia in a research report on Friday, September 27th. DA Davidson reaffirmed a “buy” rating and issued a $32.00 price target on shares of Phreesia in a research report on Thursday, September 5th. Canaccord Genuity Group reissued a “buy” rating and set a $34.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Finally, Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a report on Thursday, September 5th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.42.

Phreesia Trading Down 2.9 %

Shares of Phreesia stock opened at $19.80 on Friday. Phreesia, Inc. has a 1 year low of $12.05 and a 1 year high of $29.16. The company’s fifty day simple moving average is $23.30 and its 200-day simple moving average is $22.41. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -11.00 and a beta of 0.93. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.06. The company had revenue of $102.12 million for the quarter, compared to analyst estimates of $101.76 million. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. As a group, sell-side analysts expect that Phreesia, Inc. will post -1.23 EPS for the current year.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.